Corazon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -10.82%
- Profit Growth -78.19%
- Ebitda -32.27%
- Net Worth 6.56%
- Total Assets 4.06%
About Corazon Pharma
Corazon Pharma Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 September 2009 and has a history of 15 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Vamacell Biotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Pradip Mehta, Dilip Parekh, and Riyaz Khan serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2009PTC196106
- Company No.
196106
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Sep 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Corazon Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradip Mehta  | Director | 20-Dec-2011 | Current |
| Dilip Parekh | Director | 20-Dec-2011 | Current |
| Riyaz Khan | Director | 19-Mar-2014 | Current |
Financial Performance of Corazon Pharma.
Corazon Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 10.82% decrease. The company also saw a substantial fall in profitability, with a 78.19% decrease in profit. The company's net worth moved up by a moderate rise of 6.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Corazon Pharma?
In 2019, Corazon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Microgen Healthcare Private LimitedPradip Mehta, Dilip Parekh and 1 more are mutual person
Pay Point India Network Private LimitedPradip Mehta is a mutual person
Shri Ambe Punjinvesh Private LimitedPradip Mehta is a mutual person
- Microgen Meditech Private Limited
Riyaz Khan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Corazon Pharma?
Unlock and access historical data on people associated with Corazon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Corazon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Corazon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
